Repaglinide APi
1100 USD ($)/Kilograms
Product Details:
- Molecular Weight 452.6 Kilograms (kg)
- Storage Dry Place
- Molecular Formula C27H36N2O4
- Smell Other
- HS Code 30044090
- Taste Other
- Shelf Life 3 Years
- Click to View more
X
Repaglinide APi Price And Quantity
- 1100 USD ($)/Kilograms
- 100kg Kilograms
Repaglinide APi Product Specifications
- 135062-02-1
- Powder
- C27H36N2O4
- Blood System Agents
- Medicine Grade
- 452.6 Kilograms (kg)
- Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus
- Dry Place
- Other
- Repaglinide
- 3 Years
- 99
- Other
- 30044090
Repaglinide APi Trade Information
- Cash Against Delivery (CAD), Letter of Credit (L/C), Letter of Credit at Sight (Sight L/C), Cash in Advance (CID)
- 2 Week
- Free samples are available
- HDPE Drums
- Australia, South America, Eastern Europe, Western Europe, Middle East, Africa, Central America, Asia, North America
Product Description
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those nave to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urineOther Products in 'APIs' category
We are exporting in the countries such as Afghanistan, Algeria, Argentina, Bolivia, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Indonesia, Iran, Jordan, Morocco, Panama, South Korea, Taiwan, Turkey, Uruguay, Vietnam and Yemen.
Get in touch with us